Abbott Laboratories Corporation

Abbvie Inc.

Other

Jerome F Daanen

Arthur Gomtsyan

Michael E Kort

Erol K Bayburt

Robert G Schmidt

Philip R Kym

Eric A Voight

Michael R Schrimpf

Kevin B Sippy

Chih-hung Lee

Jianguo Ji

William H Bunnelle

Michael J Dart

Gregory A Gfesser

John R Koenig

Tammie K Jinkerson

Richard B Toupence

Teodozyj Kolasa

Andrew O Stewart

Jennifer M Frost

Meena V Patel

Anwer Basha

Pramila A Bhatia

Brian S Brown

Steven P Latshaw

Karin Rosemarie Tietje

Keith Brian Ryther

Phil B Cox

Marlon D Cowart

Anil Vasudevan

Kevin R Woller

Jeffrey J Rohde

Richard J Perner

Mark A Matulenko

Stanley DiDomenico

Jorge D Brioni

Bruce Clapham

Heath A McDonald

David A DeGoey

Lei Shi

Michael D Meyer

Ryan G Keddy

Kathleen Mortell

Anurupa Shrestha

Jun Chen

Jennifer M Pace

Steve Latshaw

Stevan Wakefield Djuric

Yun He

Nan-Horng Lin

Xueqing Wang

Sridhar Peddi

Kristine E Frank

Kenton L Longenecker

Irene I Drizin

Huaqing Liu

Derek W Nelson

Michael M Friedman

Marc J Scanio

Mark W Holladay

Kennan C Marsh

Justin D Dietrich

Noel S Wilson

Eric C Breinlinger

Henry Q Zhang

Augustine Osuma

Yihong Li

Paul P Ehrlich

Zhiren Xia

Kenneth M Engstrom

James T Wasicak

Richard L Elliott

Weili Wang

Huan-Qui Li

Ann Marie Rowley

Ahmed A Hakeem

Daniela Barlocco Cristina

Jeffrey W Ralston

Amanda W Dombrowski

Pamela S Puttfarcken

Arthur R Gomtsyan

Phil Kym

Chih-Hung Lee

Heath A Mcdonald

Michael R Kort

The invention provides tricyclic heterocyclic compounds, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variables are defined herein. The compounds of the invention may be useful for treating immunological and oncological conditions.

Tricyclic modulators of TNF signaling

Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein A, Rand Rare as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by voltage-gated sodium channels, e.g., Na1.7 and/or Na1.8. Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.

Indazole ureas and method of use

Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein G, L, Zand Zare as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by voltage-gated sodium channels, e.g., Na1.7 and/or Na1.8. Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.

(Indazol-4-yl) hexahydropyrrolopyrrolones and methods of use

Disclosed herein are modulators of TRPV3 of formula (I) wherein G, X, X, X, X, X, G, Z, R, R, u, and p are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also presented.

TRPV3 modulators

Disclosed herein are compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein X, L, R, R, G, Z, A, m, n, and p are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.

TRPV1 antagonists

Disclosed herein are compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein X, L, R, R, R, A, m, n, p, q, s, and positions a and b are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.

Disclosed herein are compounds of formula (I) or pharmaceutically acceptable salts, solvates, or combinations thereof, wherein X, X, X, X, J, K, L, X, X, R, G, and m are defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.

Disclosed herein are compounds of formula (I) or pharmaceutically acceptable salts, prodrugs, or combinations thereof, wherein X, L, R, R, R, R, R, A, m, n, p, q, and r are defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.

Disclosed herein are modulators of TRPV3 of Formula (I) wherein p is 1, 2, 3, or 4, and G, X, X, X, X, X, G, Z, R, R, and u are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also presented.

Disclosed herein are modulators of TRPV3 of formula (II): wherein G, X, X, X, X, X, G, R, R, and u are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also presented.

Disclosed herein are compounds of formula (I), or pharmaceutically acceptable salts, solvates, prodrugs, salts of prodrugs, or combinations thereof, wherein R, R, R, R, and m are defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.

Disclosed herein are compounds of formula (I) or pharmaceutically acceptable salts, solvates, prodrugs, salts of prodrugs, or combinations thereof, wherein R, R, R, R, and m are defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.

Compounds that are antagonists of the VR1 receptor, having formula (I) or a pharmaceutically acceptable salt, prodrug, or salt of a prodrug thereof, wherein A, A, A, A, R, R, R, X, Y, Z, L, n, and m, are as defined herein, and are useful in disorders prevented or ameliorated by inhibiting the VR1 receptor.

Tetrahydroquinolinyl compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor and uses thereof

The present application is directed to compounds that are TRPV1 antagonists and have formula (I) wherein variables Ar, L, R, R, R, R, R, Y, Y, and Y, are as defined in the description, which are useful for treating disorders caused by or exacerbated by vanilloid receptor activity.

Antagonists of the TRPV1 receptor and uses thereof

The present invention relates to compounds of formula (I) wherein X, R, R, R, R, R, m, and n are defined in the specification are TRPV1 antagonists. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.

Growing community of inventors

Racine, WI, United States of America

Jerome F Daanen